ESSA Pharma Inc. — Director's Dealing 2022

Jul 22, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ESSA Pharma Inc. (EPIX)
CIK: 0001633932
Period of Report: 2022-07-11

Reporting Person: BVF PARTNERS L P/IL (10% Owner)
Reporting Person: BIOTECHNOLOGY VALUE FUND L P (10% Owner)
Reporting Person: BVF I GP LLC (10% Owner)
Reporting Person: BIOTECHNOLOGY VALUE FUND II LP (See Explanation of Responses)
Reporting Person: BVF II GP LLC (See Explanation of Responses)
Reporting Person: Biotechnology Value Trading Fund OS LP (See Explanation of Responses)
Reporting Person: BVF Partners OS Ltd. (See Explanation of Responses)
Reporting Person: BVF GP HOLDINGS LLC (10% Owner)
Reporting Person: BVF INC/IL (10% Owner)
Reporting Person: LAMPERT MARK N (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4712590	Direct
Common Stock	3491779	Direct
Common Stock	357472	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Pre-funded Warrants	$0.0001	2024-08-27	Common Stock (1481634)		Direct
Pre-funded Warrants	$0.0001	2024-08-27	Common Stock (1235030)		Direct
Pre-funded Warrants	$0.0001	2024-08-27	Common Stock (203336)		Direct

Footnotes

F1: This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

F3: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

F4: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

F5: The Issuer previously issued pre-funded warrants to the Reporting Persons which are exercisable into shares of common stock at an exercise price equal to $0.0001 per share, which have an exercise period of 60 months (August 27, 2024) from the date of issuance. Each pre-funded warrant is exercisable into 1 share of common stock. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own more than 9.99% of the Issuer's outstanding shares of common stock.